A5036970226- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Histone Deacetylase Inhibitors Research
- Immune cells in cancer
- Phagocytosis and Immune Regulation
- Axon Guidance and Neuronal Signaling
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
- Lung Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Breast Cancer Treatment Studies
- Brain Metastases and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Immunotherapy and Immune Responses
- Toxin Mechanisms and Immunotoxins
- Hematopoietic Stem Cell Transplantation
Moffitt Cancer Center
2017-2025
University of South Florida
2022-2023
Levine Cancer Institute
2022
Carolinas Medical Center
2022
University of Virginia
2014
Duke University Hospital
2013
Duke Medical Center
2013
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management patients with SCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. This selection the journal focuses on metastatic (known as extensive-stage) which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms prolong survival most extensive-stage disease. Smoking cessation counseling intervention...
Abstract Purpose: Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint (ICIs). In a phase I/Ib trial, we tested the oral HDACi vorinostat combined with programmed cell death protein 1 inhibitor pembrolizumab in advanced/metastatic non–small lung cancer. Patients Methods: received intravenous (200 mg every 3 weeks) plus or 400 mg/day). Primary endpoint was safety/tolerability. Secondary endpoints included...
Abstract Lessons Learned Single-agent selinexor has limited activity in heavily pretreated patients with metastatic triple-negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated a side-effect profile consistent previous clinical trials. Future studies of this population should focus on combination approaches and biomarker-driven strategy to identify most likely benefit. Background This phase II trial evaluated the safety, pharmacodynamics, efficacy...
•Genomic instability induced by the disruption of DNA damage response pathways can increase sensitivity to immunotherapies.•Peposertib, a DNA-dependent protein kinase inhibitor, had preclinical antitumor efficacy in combination with radiotherapy.•We assessed safety and activity peposertib + avelumab ± radiotherapy advanced solid tumors.•Peposertib was well tolerated at doses ≤200 mg b.i.d. ≤250 q.d. radiotherapy.•Peposertib limited clinical activity. IntroductionWe report results from phase...
Abstract Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with PD-L1 inhibitor avelumab to assess effects coupling increased T-cell infiltration and reversal immune suppression via pepinemab sustained activation checkpoint inhibition. Patients Methods: This phase Ib/II, single-arm study was designed evaluate safety, tolerability, efficacy in 62 patients advanced non–small cell lung cancer (NSCLC), including...
e20532 Background: Chronic lymphocytic leukemia (CLL) is the most common type of and lung carcinoma second cause cancer but leading cancer-related mortality in adults, with non-small cell (NSCLC) being subtype. Newer treatments have improved survival both them individually limited data available on clinical treatment outcomes patients concurrent CLL NSCLC. Methods: A single-center retrospective analysis was conducted all at Moffitt Cancer Center diagnosed NSCLC between 01/2001- 12/2023. The...
5536 Background: Pembrolizumab is approved for PD-L1+ but not PD-L1 negative metastatic, recurrent, or persistent cervical cancer. Response rates to single agent anti-PD-1/PD-L1 therapy have been modest with no responses noted in tumors. Methods: The study designed as a prospective, phase II multi-institutional trial of SBRT followed by atezolizumab (1200 mg intravenously q3 weeks). Key eligibility criteria included patients cancer at least 2 distinct lesions. primary objective was response...
Background: The optimal treatment sequencing for patients with metastatic epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains a subject of debate. In the United States, osimertinib is preferred EGFR tyrosine kinase inhibitor (TKI) in first-line setting. However, small retrospective studies suggest that alternative TKI strategies may produce similar outcomes. This study aimed to compare outcomes NSCLC harboring an exon 19 deletion or 21 L858R mutation...
We present a comparative study on 124 patients with hematologic malignancies who had undergone reduced-intensity conditioning and then received transplant from an HLA-matched related (MRD), unrelated (MUD), or HLA-haploidentical (HAPLO) donor. The regimen, which consisted of fludarabine, melphalan busulfan, alemtuzumab was administered to lymphoid (n = 62) myeloid disease 62). Mycophenolate mofetil used as prophylaxis for graft-versus-host (GVHD), 38, 58, 33 transplants MRD, MUD, HAPLO...
9567 Background: Histone deacetylase inhibitors may enhance tumor immunogenicity through various mechanisms including induced expression of T cell chemokines. A previous phase I trial demonstrated the combination pembrolizumab (P) with vorinostat (V) in mNSCLC was well tolerated signals activity ICI-pretreated pts. We initiated a randomized first-line setting primary objective to determine if had superior ORR compared monotherapy. Methods: Pts treatment-naïve and PD-L1 ≥ 1% were eligible....
Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine inhibitors (TKIs) are highly effective for treatment of
9125 Background: Histone deacetylase inhibitors enhance tumor immunogenicity through various mechanisms including induced expression of MHC and T cell chemokines. A previous phase I trial demonstrated the combination pembrolizumab (P) with vorinostat (V) in advanced/metastatic (m)NSCLC was well tolerated signals activity ICI-pretreated pts. To further investigate combination, we conducted a first-line, II trial. Methods: Pts treatment-naïve mNSCLC PD-L1 ≥ 1% were eligible. randomized,...
Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a high-grade malignancy with limited treatment options. Despite promising results of immunotherapy in non-small cell and small lung cancers, its benefit LCNEC remains elusive. Methods: We included 24 patients diagnosed stage IV from the Moffitt Cancer Center database who received systemic therapy between January 2016 May 2021. Group A comprised first-line CT ICI (anti-PD-1 or anti-PD-L1 for ICI, n = 11), B only (n 13). The collected...
TPS3169 Background: DNA-dependent protein kinase (DNA-PK) regulates a key DNA damage response (DDR) pathway for double-strand break (DSB) repair. DNA-PK inhibition augments DSB generated by many antitumor therapies, including RT. and repair impact the interaction of tumors with immune system; combining checkpoint inhibitors (CPIs) RT + DDR-targeted agents may modulate tumor microenvironment, enhancing responsiveness to CPIs. M3814 (small molecule selective inhibitor) has demonstrated...
Immune checkpoint inhibitors (ICIs) are important novel agents used in advanced non-small cell lung cancer (NSCLC) standard regimens; however, their use increases the risk of immune-related adverse effects (IRAEs). The incidence IRAE pneumonitis is well documented ICI use. Corticosteroids continue to be mainstay treatment for IRAEs. Here we report one first cases using infliximab treat durvalumab-associated pneumonitis.